Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Kisunla
Fierce Pharma
Anti-amyloid Alzheimer's drugs show 'trivial' effects: report
The anti-amyloid drug class has yielded some FDA approvals and plenty of failures. A new analysis sheds light on how the meds have fared overall.
Eric Sagonowsky
Apr 16, 2026 11:36am
Lilly calls for improvements to Alzheimer's testing in Europe
Oct 7, 2025 9:30am
Alzheimer's trials withheld brain injury risk disclosures: NYT
Oct 24, 2024 11:33am
Lilly faces phase 2 failure of tau-targeting med
Aug 8, 2024 10:48am
